Ulrika Julku

435 total citations
16 papers, 300 citations indexed

About

Ulrika Julku is a scholar working on Oncology, Molecular Biology and Neurology. According to data from OpenAlex, Ulrika Julku has authored 16 papers receiving a total of 300 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 9 papers in Molecular Biology and 5 papers in Neurology. Recurrent topics in Ulrika Julku's work include Peptidase Inhibition and Analysis (9 papers), Signaling Pathways in Disease (8 papers) and Adenosine and Purinergic Signaling (5 papers). Ulrika Julku is often cited by papers focused on Peptidase Inhibition and Analysis (9 papers), Signaling Pathways in Disease (8 papers) and Adenosine and Purinergic Signaling (5 papers). Ulrika Julku collaborates with scholars based in Finland, Sweden and United States. Ulrika Julku's co-authors include Timo T. Myöhänen, Maria Jäntti, Stina Syvänen, Dag Sehlin, Sahar Roshanbin, Petteri Piepponen, Greta Hultqvist, Jonas Eriksson, Tobias Gustavsson and Merja H. Voutilainen and has published in prestigious journals such as Journal of Neuroscience, Scientific Reports and International Journal of Molecular Sciences.

In The Last Decade

Ulrika Julku

16 papers receiving 298 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ulrika Julku Finland 12 147 125 105 64 52 16 300
Mauro Racaniello Italy 11 202 1.4× 24 0.2× 86 0.8× 39 0.6× 91 1.8× 11 392
Mari Savolainen Finland 11 245 1.7× 117 0.9× 147 1.4× 143 2.2× 75 1.4× 13 468
Nicolas Vanhoutte Belgium 6 97 0.7× 61 0.5× 128 1.2× 43 0.7× 36 0.7× 7 274
Dae-Hoon Lee South Korea 8 291 2.0× 31 0.2× 68 0.6× 61 1.0× 144 2.8× 9 474
Anke Bill United States 12 432 2.9× 49 0.4× 82 0.8× 25 0.4× 44 0.8× 16 533
Simar Singh United States 7 179 1.2× 49 0.4× 104 1.0× 24 0.4× 38 0.7× 12 379
Zorica Ristic Switzerland 6 198 1.3× 45 0.4× 111 1.1× 10 0.2× 35 0.7× 6 385
Jia Zou China 12 168 1.1× 49 0.4× 81 0.8× 15 0.2× 100 1.9× 19 412
Aurelio Vázquez de la Torre Spain 9 164 1.1× 34 0.3× 49 0.5× 74 1.2× 88 1.7× 10 310
Junbing Wu China 11 264 1.8× 39 0.3× 135 1.3× 105 1.6× 68 1.3× 14 512

Countries citing papers authored by Ulrika Julku

Since Specialization
Citations

This map shows the geographic impact of Ulrika Julku's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ulrika Julku with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ulrika Julku more than expected).

Fields of papers citing papers by Ulrika Julku

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ulrika Julku. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ulrika Julku. The network helps show where Ulrika Julku may publish in the future.

Co-authorship network of co-authors of Ulrika Julku

This figure shows the co-authorship network connecting the top 25 collaborators of Ulrika Julku. A scholar is included among the top collaborators of Ulrika Julku based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ulrika Julku. Ulrika Julku is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Jäntti, Maria, Juha R. Savinainen, Elena Puris, et al.. (2023). A prolyl oligopeptidase inhibitor reduces tau pathology in cellular models and in mice with tauopathy. Science Translational Medicine. 15(691). eabq2915–eabq2915. 17 indexed citations
2.
Gustavsson, Tobias, Nicole G. Metzendorf, Sahar Roshanbin, et al.. (2023). Long-term effects of immunotherapy with a brain penetrating Aβ antibody in a mouse model of Alzheimer’s disease. Alzheimer s Research & Therapy. 15(1). 90–90. 19 indexed citations
3.
Julku, Ulrika, et al.. (2023). Nonpeptidic Oxazole-Based Prolyl Oligopeptidase Ligands with Disease-Modifying Effects on α-Synuclein Mouse Models of Parkinson’s Disease. Journal of Medicinal Chemistry. 66(11). 7475–7496. 8 indexed citations
4.
Roshanbin, Sahar, Ulrika Julku, Jonas Eriksson, et al.. (2022). Reduction of αSYN Pathology in a Mouse Model of PD Using a Brain-Penetrating Bispecific Antibody. Pharmaceutics. 14(7). 1412–1412. 16 indexed citations
5.
Syvänen, Stina, Silvio R. Meier, Sahar Roshanbin, et al.. (2022). PET Imaging in Preclinical Anti-Aβ Drug Development. Pharmaceutical Research. 39(7). 1481–1496. 11 indexed citations
6.
Julku, Ulrika, et al.. (2022). Brain pharmacokinetics of mono- and bispecific amyloid-β antibodies in wild-type and Alzheimer’s disease mice measured by high cut-off microdialysis. Fluids and Barriers of the CNS. 19(1). 99–99. 14 indexed citations
7.
Julku, Ulrika, et al.. (2022). Removal of proteinase K resistant αSyn species does not correlate with cell survival in a virus vector-based Parkinson's disease mouse model. Neuropharmacology. 218. 109213–109213. 8 indexed citations
8.
9.
Julku, Ulrika, et al.. (2021). Prolyl Oligopeptidase Regulates Dopamine Transporter Oligomerization and Phosphorylation in a PKC- and ERK-Independent Manner. International Journal of Molecular Sciences. 22(4). 1777–1777. 2 indexed citations
10.
Julku, Ulrika, et al.. (2019). New tricks of prolyl oligopeptidase inhibitors – A common drug therapy for several neurodegenerative diseases. Biochemical Pharmacology. 161. 113–120. 32 indexed citations
11.
Julku, Ulrika, et al.. (2019). Behavioural and dopaminergic changes in double mutated human A30P*A53T alpha-synuclein transgenic mouse model of Parkinson´s disease. Scientific Reports. 9(1). 17382–17382. 22 indexed citations
12.
Jäntti, Maria, et al.. (2019). Prolyl oligopeptidase inhibition activates autophagy via protein phosphatase 2A. Pharmacological Research. 151. 104558–104558. 38 indexed citations
13.
Penttinen, Anna‐Maija, Susanne Bäck, Merja H. Voutilainen, et al.. (2018). Combination of CDNF and Deep Brain Stimulation Decreases Neurological Deficits in Late-stage Model Parkinson’s Disease. Neuroscience. 374. 250–263. 25 indexed citations
14.
Julku, Ulrika, et al.. (2018). Removal of prolyl oligopeptidase reduces alpha-synuclein toxicity in cells and in vivo. Scientific Reports. 8(1). 1552–1552. 30 indexed citations
15.
Julku, Ulrika, Anne Panhelainen, Anne Tammimäki, et al.. (2016). Prolyl Oligopeptidase Regulates Dopamine Transporter Phosphorylation in the Nigrostriatal Pathway of Mouse. Molecular Neurobiology. 55(1). 470–482. 13 indexed citations
16.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mauro Racaniello Breakdown of academic impact, for papers by Mari Savolainen Breakdown of academic impact, for papers by Nicolas Vanhoutte Breakdown of academic impact, for papers by Dae-Hoon Lee Breakdown of academic impact, for papers by Anke Bill Breakdown of academic impact, for papers by Simar Singh Breakdown of academic impact, for papers by Zorica Ristic Breakdown of academic impact, for papers by Jia Zou Breakdown of academic impact, for papers by Aurelio Vázquez de la Torre Breakdown of academic impact, for papers by Junbing Wu
Rankless by CCL
2026